Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michael

Showing results (971-980 of 1,111) with videos related to

Pageof 112
Sort By:
The New England Journal of Medicine|October 22, 2009
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandSupachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trialScott A Wegner, Mark R Wallace, Naomi E Aronson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Journal of Virology|June 13, 2014
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison, Kara M Anasti, Frederick H Jaeger, et al.
Plos One|April 29, 2011
Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected UgandansMichael A Eller, Kim G Blom, Veronica D Gonzalez, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.
Journal of Virology|February 7, 2023
Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing AntibodiesSyna Kuriakose Gift, Lindsay Wieczorek, Eric Sanders-Buell, et al.
Journal of Virology|March 23, 2018
Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus MacaquesDenise C Hsu, Piyanate Sunyakumthorn, Matthew Wegner, et al.
Nature Biotechnology|May 26, 2015
COMPASS identifies T-cell subsets correlated with clinical outcomesLin Lin, Greg Finak, Kevin Ushey, et al.
Pageof 112

Showing results (971-980 of 1,111) with videos related to

Sort By:
Pageof 112
The New England Journal of Medicine|October 22, 2009
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandSupachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 27, 2004
Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trialScott A Wegner, Mark R Wallace, Naomi E Aronson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Journal of Virology|June 13, 2014
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramideS Moses Dennison, Kara M Anasti, Frederick H Jaeger, et al.
Plos One|April 29, 2011
Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected UgandansMichael A Eller, Kim G Blom, Veronica D Gonzalez, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.
Journal of Virology|February 7, 2023
Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing AntibodiesSyna Kuriakose Gift, Lindsay Wieczorek, Eric Sanders-Buell, et al.
Journal of Virology|March 23, 2018
Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus MacaquesDenise C Hsu, Piyanate Sunyakumthorn, Matthew Wegner, et al.
Nature Biotechnology|May 26, 2015
COMPASS identifies T-cell subsets correlated with clinical outcomesLin Lin, Greg Finak, Kevin Ushey, et al.
Pageof 112